Neurocrine Biosciences (NBIX) Nears Buy Point Amid Rising Enthusiasm

Posted on by The INO.com Team

Neurocrine Biosciences, Inc. (NBIX), a leading neuroscience-focused biopharmaceutical company, approaches the buy point amid growing market enthusiasm. The stock has surged more than 19% over the past six months and nearly 42% over the past year.

One factor fueling this optimism is NBIX's flagship product, INGREZZA®, which targets tardive dyskinesia, a movement disorder associated with certain antipsychotic medications, and its diagnosis rates have been rising. INGREZZA’s launch in 2017 has brought attention to this lesser-known condition.

Moreover, Neurocrine's early-stage initiatives targeting muscarinic receptors in the brain have captured investor interest. This research could potentially lead to new treatments for various movement disorders, schizophrenia, and other central nervous system conditions.

Now, let’s delve deeper into NBIX’s fundamentals and growth prospects:

Promising Recent Developments

On May 8, NBIX announced the initiation of its Phase 1 first-in-human clinical study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in adult participants. NBI-1117567 is an oral, investigational, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of psychiatric and neurological disorders.

On April 30, NBIX announced that the FDA approved INGREZZA® SPRINKLE capsules, introducing a new oral granules version of INGREZZA® capsules prescribed for treating adults with tardive dyskinesia and chorea linked to Huntington's disease. INGREZZA SPRINKLE offers an alternative option, particularly beneficial for individuals experiencing dysphagia or having difficulty with swallowing.

Also, Neurocrine reported positive topline data for its Phase 2 SAVITRI™ study on April 23. This was a randomized, double-blind, placebo-controlled dose-finding trial designed to evaluate the efficacy and safety of NBI-1065845 in adults with major depressive disorder (MDD).

NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) for the potential treatment for patients with MDD who have not responded adequately to at least one antidepressant during their current episode of depression.

Furthermore, in the same month, NBIX and Sentia Medical Sciences Inc. extended their research collaboration to discover novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics.

The partnership will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop, manufacture, and commercialize medicines with the potential to treat various hypothalamic-pituitary-adrenal (HPA) axis-modulated diseases.

In March, Neurocrine announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational compound NBI-1065890 in healthy adult subjects.

NBI-1065890 is a next-generation, highly potent, internally discovered, oral, selective vesicular monoamine transporter-2 (VMAT2) inhibitor for the potential treatment of certain neurological and neuropsychiatric conditions.

Moreover, NBIX is well-poised to become a leader in neuroscience, with the recent New Drug Application submissions for crinecerfont and optimistic Phase 2 results for NBI-'845 (a potential first-in-class medication for major depressive disorder).

Solid First-Quarter 2024 Financial Results

For the first quarter that ended March 31, 2024, NBIX’s revenues increased 22.6% year-over-year to $515.30 million. That surpassed the analysts’ estimate of $512.01 million. Its net product sales rose 22.7% year-over-year to $509 million, and INGREZZA net product sales were $506 million, up 23% from the prior year’s quarter.

The year-over-year growth in INGREZZA product sales was driven by solid underlying patient demand and improvement in gross-to-net dynamics. In addition, Neurocrine’s non-GAAP net income and earnings per share were $124.80 million and $1.20, compared to non-GAAP net loss and loss per share of $49.50 million and $0.51 in the first quarter of 2023, respectively.

Furthermore, as of March 31, 2024, the company’s total cash, cash equivalents and marketable securities came in at $1.91 billion, compared to $1.72 billion as of December 31, 2023.

Optimistic Analyst Expectations

Analysts expect NBIX’s revenue to increase 20.9% year-over-year to $547.13 million for the second quarter ending June 2024. The consensus EPS estimate of $1.49 for the current quarter indicates an improvement of 19.3% year-over-year. Moreover, Neurocrine has topped consensus revenue and EPS estimates in three of the trailing four quarters, which is remarkable.

Additionally, NBIX’s revenue and EPS for the fiscal year (ending December 2024) are expected to grow 17.7% and 54.8% year-over-year to $2.22 billion and $5.98, respectively. For the fiscal year 2025, Street expects the company’s revenue and EPS to increase 14.4% and 22.9% from the previous year to $2.54 billion and $7.34, respectively.

Pharma Industry’s Favorable Trends And Dynamics

The growing population worldwide, aging demographics, and increasing prevalence of chronic diseases are boosting the demand for pharmaceutical products and healthcare services. Furthermore, regulatory agencies are increasingly implementing expedited review pathways and flexible approval processes to accelerate innovation and access to new treatments.

According to Statista, the revenue in the pharmaceuticals market is projected to reach $1.16 trillion in 2024. In global comparison, the U.S. is expected to generate the highest revenue of $636.90 billion this year. Looking ahead, the revenue in this sector is expected to grow at a CAGR of 6.2% from 2024 to 2028, resulting in a market volume of $1.47 trillion by 2028.

Moreover, biopharmaceutical advancements, growing adoption of precision medicine approaches, increasing investments in specialty drugs targeting specific diseases or patient populations, and orphan drugs for rare diseases are key trends shaping the pharma sector.

As per IQVIA, U.S. medicines spending is projected to grow 4 to 7% through 2028. This growth will be fueled by the adoption of newly launched innovative products, with an average of 50-55 new medicines launching per year over the next five years, such as those in oncology or with orphan status, alongside a few traditional therapies in diabetes, neurology, and obesity.

Accelerating Profitability

NBIX’s trailing-12-month gross profit margin of 68.54% is 21.7% higher than the 56.34% industry average. Likewise, the stock’s trailing-12-month EBIT margin and levered FCF margin of 23.73% and 36.29% are significantly higher than the industry average of 0.53%, respectively.

Moreover, the stock’s trailing-12-month net income margin of 18.65% compared to the industry average of negative 5.52%. Its trailing-12-month ROCE, ROTC, and ROTA of 18.16%, 12.36%, and 10.65% favorably compared to the respective industry averages of negative 40.87%, negative 20.89%, and negative 29.54%.

Bottom Line

Neurocrine reported outstanding first-quarter 2024 results, with revenue exceeding analyst expectations. The neuroscience-focused biopharmaceutical company’s INGREZZA® net product sales were a significant contributor, posting a 23% year-over-year growth, driven by solid patient demand and improvements in gross-to-net-dynamics. 

NBIX’s CEP, Kevin Gorman, Ph.D., highlighted the continued need for treatment for patients with tardive dyskinesia, expressing confidence in the company's lead product, INGREZZA.

For the fiscal year 2024, the company expects INGREZZA net product sales to range from $2.10 to $2.20 billion.

Moreover, Neurocrine is actively pursuing strategic initiatives to develop medicines to alleviate the burden of debilitating diseases and disorders. This includes their ongoing research and development (R&D) efforts to create new effective treatments for neurological, neuroendocrine, and neuropsychiatric conditions.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on NBIX, with a price target of $170. Mohit Bansal has given a Buy rating due to several factors indicating a solid business foundation and bright future developments for Neurocrine. The company’s flagship product, INGREZZA, has been a robust performer, contributing to operating margin expansion and serving as a solid base for the business.

Furthermore, according to the analyst, Neurocrine is actively preparing to launch crinecerfont, its upcoming new drug, with management expressing confidence in its chances for priority review by the FDA. Bansal also highlights the company's proactive approach to ensuring study quality, which bodes well for future clinical trials.

Considering these factors, it could be wise to scoop up shares of NBIX for potential gains.

Investing Like a Billionaire: Everything Berkshire Hathaway Offers to Ordinary Investors

Posted on by The INO.com Team

With a $867.46 billion market cap, Berkshire Hathaway (BRK.A) (BRK.B), a diversified holding company, is led by Warren Edward Buffett, who is one of the world’s renowned investors with a long track record of successful capital allocation and value creation. As of May 8, 2024, he has a net worth of $133.50 billion, making him the eighth-richest person in the world.

Buffett’s substantial wealth primarily stems from his significant holdings in Berkshire Hathaway, a conglomerate with assets exceeding $1 trillion. Under Buffett’s expertise and exceptional leadership, Berkshire has historically delivered robust and consistent long-term growth, outperforming various other investment options.

From 1965, when Warren Buffett took control of the company, to 2023, Berkshire’s share price surged by a staggering 4,384,748%, surpassing the total return of the S&P 500 with dividends included of 31,223%. Additionally, Berkshire has continued its solid performance into 2024, with a double-digit percentage gain.

Berkshire’s Portfolio Reflects Buffett’s Investment Strategy

Known as the “Oracle of Omaha,” Warren Buffett stands out as one of the most accomplished investors of all time. He follows the Benjamin Graham school of value investing, seeking out securities with unreasonably low prices compared to their intrinsic worth. He often assesses the company’s long-term potential rather than short-term market trends.

Buffett considers company performance, profit margins, management team, and business model. He believes in investing in high-quality businesses with solid competitive advantages or “economic moats,” enabling them to maintain or expand their market share over time.

Sticking to his investment policy, Buffett’s holding company, Berkshire Hathaway, aims to “buy ably-managed businesses” possessing various characteristics, such as enduring competitive advantage, at extremely low prices.

For instance, the acquisition of See’s Candies in 1972 demonstrated Buffett’s strategy, as the company's robust brand and loyal customer base made it a highly profitable long-term investment. He favors companies with strong brands and business models that own their market niche, creating formidable barriers for competitors trying to enter and beat them at their game.

Berkshire Offers Diversification Across Industries

Berkshire Hathaway’s top holding is Apple Inc. (AAPL). Thanks to its strong brand and customer loyalty, it has remained one of Buffett’s favorite stocks for a long time. He has previously referred to AAPL as the “best business I know in the world.”

BRK.B recently disclosed that it had cut its stake in Apple by around 13% in the first quarter. It was reported that Berkshire’s Apple bet was worth $135.4 billion, implying nearly 790 million shares. Despite this trim, the iPhone maker is still Berkshire’s biggest holding by far, with a 39.8% weight in its publicly traded portfolio.

Another consumer goods company that Buffett loves is The Coca-Cola Company (KO). He recognized the company’s iconic brand, attractive dividends, and market advantages. Coca-Cola’s robust brand has enabled it to mitigate the impact of inflation by transferring higher costs to customers while still being able to generate growth.

At around 6.9%, KO is the fourth-largest holding in Berkshire’s portfolio. Berkshire owns a 9.3% stake in the company.

Meanwhile, Warren Buffett holds significant investments in the energy sector. During the fourth quarter of 2023, Buffett’s Berkshire increased its stakes in two major oil and gas companies, Chevron Corporation (CVX) and Occidental Petroleum Corporation (OXY).

Berkshire Hathaway owns about a 6.7% stake in CVX. According to Berkshire’s February shareholder letter, the firm also holds a 27.8% stake in OXY and has warrants to increase its ownership further at a fixed price.

Chevron (about 5.5% of the portfolio’s total weight) and Occidental (4.5%) provide investors with exceptionally good returns amid the inflationary periods and pay attractive dividends.

In addition, Buffett is fond of financial institutions and insurance companies, viewing them as a strategic bet on the long-term health of the U.S. economy. Berkshire's top two financial holdings are Bank of America Corporation (BAC) and American Express Company (AXP). These financial stocks comprise approximately 21% of the Berkshire portfolio’s total weight.

Outstanding First-Quarter Operating Earnings and Record Cash Hoard

For the first quarter that ended March 31, 2024, Berkshire’s total revenues increased 5.3% year-over-year to $89.87 billion. Revenues from Railroad, Utilities and Energy rose 11.2% year-over-year, and revenues from Insurance and Other grew 3.2%.

The Warren Buffett-led conglomerate reported first-quarter operating profit, which encompasses earnings from the company’s wholly-owned businesses, grew 39% from the year-ago period to $11.22 billion. This remarkable surge was led by a 185% year-over-year increase in insurance underwriting earnings to $2.60 billion. Insurance investment also soared 32% to over $2.50 billion.

However, net earnings attributable to Berkshire Hathaway shareholders declined by 64.2% year-over-year to $12.70 billion.

During the first quarter, the company’s cash pile reached a record high of $188.99 billion, up from $167.60 billion in the fourth quarter.

“We had much-improved earnings in insurance underwriting. And then our investment income was almost certain to increase,” Buffett said at Berkshire’s annual shareholder meeting in Omaha, Nebraska. “And I said that in the annual report because yields are so much higher than they were last year. And we have a lot of fixed, short-term investments that are very responsive to the changes in interest rates.”

Bottom Line

Berkshire Hathaway, led by a well-known investor, Warren Buffett, follows an intrinsic value investing approach, aiming at buying undervalued companies with solid fundamentals, competitive advantages, and long-term growth potential. Berkshire owns a diverse portfolio of businesses, including insurance, utilities, transportation, retail, and technology, among others.

Moreover, Berkshire’s top five holdings pay attractive dividends, which indicates Warren Buffett’s interest in stocks that offer a stable income stream.

Buffett’s conglomerate recently reported a significant surge in operating earnings in the first quarter of fiscal 2024, primarily driven by an increase in insurance underwriting earnings and a record cash pile that nears $200 billion.

USB analyst Brian Meredith maintained a Buy rating on Berkshire, citing the recent earnings beat and noting that Geico is on track to catch up to rivals Progressive and others on data analytics by 2025.

Berkshire Hathaway has historically delivered impressive and consistent returns. From 1965 to 2023, its share price skyrocketed 4,384,748%, more than 140 times the total return of the S&P 500, with dividends included. Moreover, Berkshire shares have already outperformed this year, with each share class having advanced more than 12%, while the S&P is up by nearly 8%.

Shares of BRK.B have gained approximately 16% over the past six months and more than 22% over the past year.

Looking ahead, analysts expect BRK.B’s EPS for the fiscal year (ending December 2024) to increase 14.6% year-over-year to $19.70. Further, the company’s EPS and revenue for the fiscal year 2025 are expected to grow 1.4% and 5.6% from the prior year to $19.97 and $376.61 billion, respectively.

Thus, by owning BRK.B shares, investors can gain exposure to Berkshire’s diversified portfolio of businesses, Buffett’s expertise, and stable growth and performance.

Why Super Micro Computer (SMCI) Could Be a Hidden Gem for Growth Investors

Posted on by The INO.com Team

In March 2024, Super Micro Computer, Inc. (SMCI) became the latest artificial intelligence (AI) company to join the S&P 500 index, just a little more than a year after joining the S&P MidCap 400 in December 2022. Shares of SMCI jumped by more than 2,000% in the past two years, driven by robust demand for its AI computing products, which led to rapid sales growth.

Moreover, SMCI’s stock has surged nearly 205% over the past six months and more than 520% over the past year. A historic rally in the stock has pushed the company’s market cap past $48 billion.

SMCI is a leading manufacturer of IT solutions and computing products, including storage and servers tailored for enterprise and cloud data centers, purpose-built for use cases such as AI, cloud computing, big data, and 5G applications. The company has significantly benefited from the ongoing AI boom in the technology sector.

According to ResearchAndMarkets.com’s report, the global AI server market is expected to reach $50.65 billion by 2029, growing at a CAGR of 26.5% during the forecast period (2024-2029).

Specializing in servers and computer infrastructure, SMCI maintains long-term alliances with major tech companies, including Nvidia Corporation (NVDA), Intel Corporation (INTC), and Advanced Micro Devices, Inc. (AMD), which have fueled the company’s profitability and growth.

Let’s discuss Super Micro Computer’s fundamentals and growth prospects in detail:

Recent Strategic Developments

On April 9, SMCI announced its X14 server portfolio with future support for the Intel® Xeon® 6 processor with early access programs. Supermicro’s Building Block Architecture, rack plug-and-play, and liquid cooling solutions, along with the breadth of the new Intel Xeon 6 processor family, enables the delivery of optimized solutions for any workload and at any scale, offering superior performance and efficiency.

The upcoming processor family will be available with Efficient-core (E-core) SKUs rising performance-per-watt for cloud, networking, analytics, and scale-out workloads, and Performance-core (P-core) SKUs increasing performance-per-core for AI, HPC, Storage and Edge workloads. 

Also, the upcoming processor portfolio will feature built-in Intel Accelerator Engines with new support for FP16 on Intel Advanced Matrix Extensions.

In the same month, SMCI expanded its edge compute portfolio to accelerate IoT and edge AI workloads with a new generation of embedded solutions.

“We continue to expand our system product line, which now includes servers that are optimized for the edge and can handle the demanding workloads where massive amounts of data are generated,” said Charles Liang, president and CEO of SMCI.

“Our building block architecture allows us to design and deliver a wide range of AI servers that give enterprises the solutions they need, from the edge to the cloud. Our new Intel Atom-based edge systems contain up to 16GB of memory, dual 2.5 GbE LAN ports, and a NANO SIM card slot, which enables AI inferencing at the edge where most of the world's data is generated,” Liang added.

Also, on March 19, Supermicro unveiled its newest lineup aimed at accelerating the deployment of generative AI. The Supermicro SuperCluster solutions offer foundational building blocks for the present and the future large language model (LLM) infrastructure.

The full-stack SuperClusters include air- and liquid-cooled training and cloud-scale inference rack configurations with the latest NVIDIA Tensor Core GPUs, Networking, and NVIDIA AI Enterprise software.

Further, SMCI announced new AI systems for large-scale generative AI featuring NVIDIA's next-generation of data center products, such as the latest NVIDIA GB200 Grace™ Blackwell Superchip, the NVIDIA B200 Tensor Core, and B100 Tensor Core GPUs.

Supermicro is upgrading its existing NVIDIA HGX™ H100/H200 8-GPU systems for seamless integration with the NVIDIA HGX™ B100 8-GPU, thus reducing time to delivery. Also, the company strengthens its broad NVIDIA MGX™ systems range with new offerings featuring the NVIDIA GB200, including the NVIDIA GB200 NVL72, a comprehensive rack-level solution equipped with 72 NVIDIA Blackwell GPUs.

Additionally, Supermicro is introducing new systems to its portfolio, including the 4U NVIDIA HGX B200 8-GPU liquid-cooled system.

Solid Third-Quarter 2024 Results

For the third quarter that ended March 31, 2024, SMCI’s revenue increased 200.8% year-over-year to $3.85 billion. Its non-GAAP gross profit grew 163.9% from the year-ago value to $600.59 million. Its non-GAAP income from operations was $434.42 million, up 290.7% year-over-year.

The server assembler’s non-GAAP net income rose 340% from the prior year’s quarter to $411.54 million. Its non-GAAP net income per common share came in at $6.65, an increase of 308% year-over-year.

As of March 31, 2024, Super Micro Computer’s cash and cash equivalents stood at $2.12 billion, compared to $440.46 million as of June 30, 2023. The company’s total current assets were $8.06 billion versus $3.18 billion as of June 30, 2023.

Charles Liang, President and CEO of Supermicro, said, “Strong demand for AI rack scale PnP solutions, along with our team’s ability to develop innovative DLC designs, enabled us to expand our market leadership in AI infrastructure. As new solutions ramp, including fully production ready DLC, we expect to continue gaining market share.”

Raised Full-Year Revenue Outlook

SMCI expects net sales of $5.10 billion to $5.50 billion for the fourth quarter of fiscal year 2024 ending June 30, 2024. The company’s non-GAAP net income per share is anticipated to be between $7.62 and $8.42.

For the fiscal year 2024, Supermicro raised its guidance for revenues from a range of $14.30 billion to $14.70 billion to a range of $14.70 billion to $15.10 billion. Its non-GAAP net income per share is expected to be from $23.29 to $24.09.

CEO Charles Liang said he expects AI growth to remain solid for several quarters, if not years, to come. To support this rapid growth, the company had to raise capital through a secondary offering this year, Liang added.

Meanwhile, finance chief David Weigand said that the company’s supply chain continues to improve.

Bottom Line

SMCI’s fiscal 2024 third-quarter results were exceptional, with a record revenue of $3.85 billion and a non-GAAP EPS of $6.65. This year-over-year revenue growth of 200% and year-over-year non-GAAP EPS growth of 308% significantly outpaced its industry peers.

After reporting outstanding financial performance, the company raised its full-year revenue forecast as it points to solid AI demand.

Super Micro Computer, which joined the S&P 500 in March, has a unique edge among server manufacturers aiming to capitalize on the generative AI boom. Notably, the server maker’s close ties with Nvidia allow it to launch products superior to competitors, including Dell Technologies Inc. (DELL) and Hewlett Packard Enterprise Company (HPE).

The company has a history of being among the first to receive AI chips from NVDA and AMD as it assists them in checking server prototypes, giving it a head start over rivals. This has positioned SMCI as a key supplier of servers crucial for generative AI applications, leading to a remarkable 192% surge in shares so far this year.

According to an analyst at Rosenblatt Securities, Hans Mosesmann, “Super Micro has developed a model that is very, very quick to market. They usually have the widest portfolio of products when a new product comes out from Nvidia or AMD or Intel.”

Moreover, analysts at Bank of America project that SMCI’s share of the AI server market will expand to around 17% in 2026 from 10% in 2023. Argus analyst Jim Kelleher also seems bullish about SMCI. Kelleher maintained a Buy rating on SMCI’s stock.

According to the analyst, Super Micro Computer is a leading server provider for the era of generative AI. Alongside a comprehensive range of rack and blade servers for cloud, enterprise, data center, and other applications, SMCI offers GPU-based systems for deep learning, high-performance computing, and various other applications.

Given solid financials, accelerating profitability, and robust near-term growth outlook, investors could consider buying this stock for substantial gains.

Can Starbucks (SBUX) Rebound From Earnings Miss?

Posted on by The INO.com Team

Starbucks Corporation (SBUX), the leading coffeehouse chain, reported quarterly revenue and EPS that fell short of analysts’ expectations. Shares of SBUX declined more than 12% in premarket trading Wednesday after the coffee company reported a disappointing quarter. Also, the stock has plunged nearly 18% over the past month and almost 28% over the past six months.

For the second quarter that ended March 31, 2024, SBUX’s net revenues decreased 1.8% year-over-year to $8.56 billion. That missed analysts’ revenue estimate of $9.16 billion.

Global same-store sales decreased by 4% as traffic to its cafes declined 6% in the quarter. Starbucks experienced declining same-store sales and lower traffic across all regions. In North America and the U.S., same-store sales dropped by 3% as traffic fell 7%, marking the second consecutive quarter of challenges in its home market.

Last quarter, executives attributed slow sales to boycotts of the stores related to misperceptions about its stance on Israel.

SBUX’s CEO Laxman Narismhan told analysts on the company’s conference call, “In this environment, many customers have been more exacting about where and how they choose to spend their money.” Narasimhan added that a deteriorating economic outlook in several of its markets had contributed to a significant reduction in customer traffic.

SBUX’ International segment posted same-store sales declines of 6%, with both average ticket and transactions declining. In China, the company's second-largest market, same-store sales fell by 11%, primarily due to an 8% reduction in average ticket.

The coffee giant’s operating income was $1.10 billion, down 17.2% from the prior year’s quarter. Net earnings attributable to SBUX declined 15% year-over-year to $772.40 million. It reported net earnings per share was $0.68, compared to the consensus estimate of $0.80, and down 13.9% year-over-year.

As of March 31, 2024, Starbucks’ cash and cash equivalents stood at $2.76 billion, compared to $3.55 billion as of October 1, 2023. The company’s current assets were $6.47 billion versus $7.30 as of October 1, 2023.

“In a highly challenged environment, this quarter’s results do not reflect the power of our brand, our capabilities or the opportunities ahead,” said Laxman Narasimhan. “It did not meet our expectations, but we understand the specific challenges and opportunities immediately in front of us.”

“We have a clear plan to execute and the entire organization is mobilized around it. We are very confident in our long-term and know that our Triple Shot Reinvention with Two Pumps strategy will deliver on the limitless potential of this brand,” Narasimhan added.

Meanwhile, Rachel Ruggeri, SBUX’s chief financial officer, commented, “While it was a difficult quarter, we learned from our own underperformance and sharpened our focus with a comprehensive roadmap of well thought out actions making the path forward clear.”

“On this path, we remain committed to our disciplined approach to capital allocation as we navigate this complex and dynamic environment,” he added. 

Bleak Fiscal 2024 Outlook

For the fiscal year 2024, SBUX expects revenue growth in the low single digits, compared to the prior guidance of 7% to 10%. The coffee giant also revised its forecasts for global and U.S. same-store sales growth to a range of low single digits to flat from its prior projection of 4% to 6%.

Starbucks’ same-store sales in China are anticipated to decrease by single digits, compared to the previous guidance of a single-digit increase. The company further expects EPS growth to range from flat to low single digits. Previously, it expected its earnings to surge 15% to 20% in 2024.

However, the company projects that sales might improve in the fourth quarter of 2024.

In addition, SBUX’s CEO Narasimhan said that the company now expects supply-chain cost savings of $4 billion over the next four years, revising its previous outlook of $3 billion over three years.

Strategic Initiatives

In February 2024, SBUX and Bank of America Corporation (BAC), the prominent financial institution, announced a new collaboration that offers millions of Bank of America cardholders and Starbucks Rewards® members in the U.S. the ability to earn more benefits by linking accounts.

Bank of America cardholders and Starbucks Rewards members can earn an additional 2% cash back on qualifying purchases on top of their existing rewards or card benefits. Additionally, they can earn 1 Star per $2 spent at Starbucks by linking an eligible debit or credit card to their Starbucks Rewards account at BofA.com/starbucks or starbucks.com/bofa.

Ryan Butz, vice president of loyalty strategy and marketing at Starbucks, said, “This partnership is the latest example of how we are continuing to invest in our most loyal customers to deepen engagement and connection by offering benefits and experiences that can’t be found anywhere else.”

Despite near-term macroeconomic headwinds, the Seattle-based coffee company remains focused on its long-term growth and outsized returns to partners, customers, and shareholders.

In November last year, SBUX announced its long-term growth strategy, Triple Shot Reinvention with Two Pumps, to elevate the brand, strengthen and scale digital, identify opportunities within and outside the store for efficiencies, expand globally, and reinvigorate the partner (employee) culture. 

For the quarter that ended March 31, 2024, Starbucks’ U.S. store count stood at 16,600, a 3% increase year-over-year. The company aspires to reach 20,000 over the long term, leveraging the vast channels available to meet the changing customer needs and further elevate the brand.

“Innovation in our store formats, to purpose defined stores like pick-up, drive-thru only, double-sided drive-thru, and delivery-only allows us to better meet our customers where they are at through differentiated experiences,” said Sara Trilling, executive vice president and president of Starbucks North America.

In addition, the brand will be elevated via product innovation. Also, SBUX introduced a new phase in the acceleration of its digital flywheel. The coffee chain wants to strengthen its digital leadership with a strategy aimed at Double global Starbucks Rewards with another 75 million members within the next five years.

Also, SBUX announced new technology collaborations to improve the partner and customer experience. The partnership with Microsoft Corporation (MSFT) will continue through joint efforts in its innovation lab, combining industry-leading generative AI capabilities to advance product development and personalization to the next level.

Further, Starbucks will collaborate with Apple (AAPL) products in its first Green Apron Innovation store to experiment and refine technology to help partners worldwide. The company will also reimage the customer in-store experience with Amazon One and Just Walk Out technology. 

SBUX also announced a plan to expand its global store footprint to 55,000 by 2030, bolstered by further expansion of digital platforms across all licensed partners worldwide. 

The company further announced the implementation of a $3 billion efficiency program – with $2 billion outside the store in cost of goods sold – to reinvest in the business and deliver returns to shareholders through margin expansion and earnings growth.  

Bottom Line

SBUX reported weaker-than-expected revenue and earnings in the second quarter of fiscal 2024, driven by a significant decline in same-store sales. After a disastrous quarter, the coffee giant lowered its outlook for the full-year earnings and revenue; however, it forecasts sales will start improving in the fourth quarter of 2024.

Regarding disappointing financial performance, CEO Laxman Narasimhan said customers had been more cautious about where and how they spend their money during the quarter. The U.S. consumer confidence deteriorated for the third consecutive month in April as consumers continued to fight persistently high prices and elevated interest rates.

Starbucks added that bad weather also closed some U.S. stores briefly in the quarter. China, the company's second-largest market, also witnessed a choppy post-COVID recovery. Further, it is facing an ongoing boycott of its stores for its perceived support of Israel in the war in Gaza.

Despite near-term macro challenges, the coffee giant stays committed to its long-term growth strategy, Triple Shot Reinvention with Two Pumps, which priorities elevating the Starbucks brand, strengthening the company’s digital capabilities, becoming more global by accelerating store expansion, unlocking efficiency by cost savings, and reinvigorating the partner culture.

Starbucks continues to deliver significant value to partners, customers, and shareholders. On March 21, SBUX’s Board of Directors approved a quarterly cash dividend of $0.57 per share of outstanding common stock, payable in cash on May 31, 2024.

SBUX pays an annual dividend of $2.28 per share, which translates to a yield of 3.12% on the current share price. Its four-year average dividend yield is 2%. The company’s dividend payouts have grown at a CAGR of 9.8% over the past five years. Moreover, Starbucks has raised its dividend for 13 consecutive years.

Although the road to recovery might be rocky, investors should watch closely for improvements in SBUX’s same-store sales, gains from ongoing strategic initiatives, and global store expansion. Hence, it could be wise to wait for a better entry in this stock for now.

Is Boeing (BA) a Recovery Play? Evaluating Upside Potential and Risks

Posted on by The INO.com Team

The Boeing Company (BA), a stalwart in aircraft manufacturing and services, has faced a cascade of challenges so far this year. Just as the dust was settling on its mid-air blowout incident in January, another report emerged of a plane having mechanical failures, though this one is somewhat different from the reports we’ve already heard.

This time, it's a Delta flight from New York to Los Angeles, reporting a problem with the emergency slide on the right wing and a strange sound. While this isn't good news for Boeing, given that the plane is quite old (flying since 1990), it's not expected to cause too much trouble either.

Now, let’s evaluate the upside potential and risks associated with investing in BA, considering factors like financials, growth prospects, valuation, and industry dynamics.

A Tumultuous Start to 2024

Boeing and its aircraft manufacturer have faced significant media attention since the start of 2024, with a series of incidents prompting investigations. In January, an Alaska Airlines Boeing 737 MAX 9 had to make an emergency landing in Portland, Oregon, because a part of the plane's fuselage blew out.

Although there were no casualties, the U.S. National Transportation Safety Board (NTSB) investigation revealed that the door was not properly secured due to missing bolts. As a result, it led to a grounding of its 737-9 MAX fleet, increased scrutiny of the plane maker’s 737 production and safety processes, and decreased overall plane production.

Later in January, an ANA (All Nippon Airways) Boeing 737-800 had to return to Japan after a crack was found on its cockpit window during flight.

On February 21, a United Airlines Boeing 757-200 made an emergency landing in Denver due to wing damage. Furthermore, in March, a United Airlines Boeing 777-200 had to land in Los Angeles after a tire fell off following take-off, damaging vehicles below.

Other incidents include a brief rudder control failure on a Boeing 737 Max in New Jersey, a United Airlines Boeing 737 MAX 8 going off the taxiway in Houston, and a Boeing 737 in Medford, Oregon, being found missing a panel.

Further, on March 18, an Alaska Airlines Boeing 737 had a cracked windshield upon landing in Portland.

Can Boeing Be Trusted Again?

Such incidents have dealt a significant blow to the company, raising concerns about BA’s approach of prioritizing profits over safety. Particularly, the Alaska Airlines incident led to tighter regulatory scrutiny, financial implications, and demands for compensation, potentially hampering Boeing's growth trajectory.

However, the company has taken steps to improve quality, including expanding inspections, changing how work is performed, increasing training, and soliciting more feedback from employees.

“We are absolutely committed to doing everything we can to make certain our regulators, customers, employees and the flying public are 100 percent confident in Boeing,” Dave Calhoun, Boeing’s chief executive officer, said in a letter to employees last week.

Moreover, the company is also in talks to acquire Spirit AeroSystems Holdings, Inc. (SPR), a troubled supplier that builds the body of the Max jet, which had been a part of Boeing until it was spun out two decades ago. This potential acquisition reflects Boeing's commitment to streamlining its supply chain, strengthening production capabilities, and exerting greater control over supplier policies and practices.

Disappointing Financial Performance

Despite a rocky start this year, Boeing reported a slightly better-than-feared quarter but continued to burn cash (almost $4 billion) as it tried to stabilize production. With fewer planes exiting factories in the last three months, Boeing's revenue suffered a significant blow in the first quarter.

For the quarter that ended March 31, 2023, the company posted a 7.5% year-over-year decline in its total revenues to $16.57 billion. Its non-GAAP core operating loss came in at $388 million and $1.13 per share, respectively. Also, BA’s net loss for the quarter amounted to $355 million, which was not as steep as analysts had expected, and it was smaller than the $425 million loss in the prior year’s period.

Deliveries of Boeing's commercial planes declined by 36% year-on-year in the first three months of 2024. The airline company also reported an operating cash outflow of $3.36 billion, compared with $318 million cash outflow in the last year’s period. Also, it posted a negative free cash flow of $3.92 billion, compared with a loss of $787 million a year ago. Further, the total company backlog grew to $529 billion, including over 5,600 commercial airplanes.

CEO Dave Calhoun, emphasizing the ‘tough moment,’ said, “Lower deliveries can be difficult for our customers and for our financials. But safety and quality must and will come above all else.”

Mixed Analyst Expectations

As Boeing continues to face substantial expenses in resolving identified issues, compensating affected parties, and handling potential legal matters, CFO Brian West believes the company will have a “sizable use of cash” in the second quarter.

Analysts expect BA’s revenue for the fiscal year (ending December 2024) to increase 4.2% year-over-year to $81.09 billion. However, the company is expected to report a loss per share of $0.55. For the ongoing quarter ending June 2024, its revenue is estimated to decline 3.6% year-over-year to $19.05 billion.

However, Street expects the company’s revenue for the next quarter (ending September 30, 2024) to increase by 18.5% year-over-year to $21.46 billion, while its earnings per share is expected to be at $0.41.

During this challenging period, Calhoun stated, “We are utilizing this period, challenging as it may be, to intentionally reduce the pace of operations, strengthen the supply chain, enhance our factory operations, and position Boeing to consistently deliver the reliability and quality our customers expect in the long run.”

Bottom Line

BA’s ongoing challenges, including numerous safety issues, production halts, and delayed deliveries, have put the firm in a complex situation where forecasting future demand has become increasingly precarious. These headwinds are significantly impacting its airline customer base, leading to declining profitability, cash flow problems, and inventory issues that might linger for a while.

Despite these short-term hurdles, the company is committed to strengthening its market position, achieving long-term growth outlooks, and improving predictability for both customers and investors. But this process is going to take some time and concerted effort.

Ultimately, the market's confidence in Boeing depends on its ability to bounce back from its current challenges. However, the question remains: can the recovery be achieved soon?

Regarding price performance, the stock has plunged nearly 15% over the past three months and more than 33% year-to-date.

Moreover, the stock seems pretty pricey at the moment. In terms of forward P/E, BA is currently trading at 142.59x, which is substantially higher than the industry average of 23.99x. The stock’s forward EV/Sales of 1.81x is 2.9% higher than the industry average of 1.76x. Also, its forward EV/EBITDA of 33.92x compares to the industry average of 11.30x.

Besides, BA’s trailing-12-month gross profit and levered FCF margins of 11.48% and 4.01% are 62.7% and 38.9% lower than the industry averages of 30.80% and 6.56%, respectively. Also, its net income margin of negative 2.81% compares to the industry average of 5.86%.

Recently, Argus Research downgraded their outlook for BA stock from Buy to Hold, estimating a target price of $243.01, indicating a 40.1% upside. In addition, Northcoast Research downgraded the stock from Neutral to Sell.

Given these factors, we believe waiting for a better entry point in this stock could be wise now.